Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

193P - Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstial lung disease


03 Apr 2022


Poster Display session


Tumour Site

Thoracic Malignancies


Célia Joseph


Annals of Oncology (2022) 33 (suppl_2): S117-S121. 10.1016/annonc/annonc858


C. Joseph1, M. Delaunay1, A. Lusque2, J. Michot3, R. Veillon4, M. Wislez5, P. Tomasini6, E. Giroux-Leprieur7, M. Duruisseaux8, M. Perol9, C. Decroisette10, B. Duchemann11, S. Couraud12, J. Milia1, S. Collot1, G. Prevot1, J. Le Pavec13, J. Mazieres14

Author affiliations

  • 1 Hôpital Larrey, Toulouse/FR
  • 2 Institut Claudius Regaud, Toulouse/FR
  • 3 Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 CHU Bordeaux, Bordeaux/FR
  • 5 Hôpital Cochin, Nogent sur Marne/FR
  • 6 Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 7 Hopital Ambroise Pare AP-HP, Boulogne-Billancourt/FR
  • 8 Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon/FR
  • 9 Centre Léon Bérard, Lyon/FR
  • 10 Le Centre Hospitalier Annecy Genevois, Metz-Tessy/FR
  • 11 Hôpital Avicenne, Bobigny/FR
  • 12 Lyon Sud Hospital Center - HCL, Pierre-Bénite/FR
  • 13 Hopital Saint Joseph, Paris/FR
  • 14 Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse/FR

Abstract 193P


Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events. Rechallenge after a first episode of ILD remains controversial.


We conducted a multicenter retrospective cohort study of ICIs rechallenge after a first episode of an ICI-associated with interstitial lung disease (ICI-ILD). The objective was to evaluate the safety and efficacy of immunotherapy rechallenge.


Thirty-two patients were included and were initially treated with anti-PD-1 monotherapy (84.4%) or in combination with anti-CTLA-4 (15.6%) and experienced grade 1 (25%), grade 2 (56.2%) grade 3 (18,8%) ICI-ILD. Most patients (90.6%) were rechallenged with anti-PD-1 monotherapy. Thirteen patients (40.6%) experienced ILD recurrence following rechallenge. Median time to recurrence of ICI-ILD after ICI rechallenge was shorter for the recurrence vs for the first episode: 0.9 (range: 0.2-8.3) vs 3.0 (0.03-35.7) months. The second episode of ICI-ILD appeared to be more severe than the first one, regarding both symptoms (38.5% vs 18.8 % of grade ≥ 3 ILD), and radiological features (higher number of lobes and intensity of CT-scan lesions after centralized review). One ICI-ILD related death was reported. 53.8% of patients recurred with a similar radiological pattern. Steroids use during rechallenge was not associated with ICI-ILD recurrence risk. Objective response rate and disease stabilization under ICI rechallenge were at 18.8% and 34.4%. Progression free survival and overall survival were not statistically different in patients who experienced ICI-ILD recurrence vs not. Three months after the rechallenge, 15 patients (46.9%) had progressive disease: 55.6% in the recurrence group and 43.6% in the no recurrence group.


40.6% of patients had a recurrence of ICI-ILD after rechallenge with ICI. The second episode of ICI-ILD appears to have similar radiological patterns but to be more severe and to occur earlier than the first one.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.